COMP <GO>
MYGN vs MRK // DIVIDEND YIELD & FCF PAYOUT SAFETY
Myriad Genetics Inc. (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: MYGN 1
— MRK 10
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MRK
LAST: $6.35 (-4.80%) • MKT CAP: $638.0M
dividend-safety
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
dividend-safety
2.26%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (MYGN VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | MYGN | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 69.90% | 74.80% | -4.90 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -35.00% | 20.70% | -55.70 | MRK | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | 0.28% | 3.42% | -3.14 | MRK | /fcf-yield <GO> |
| Operating Margin | -47.00% | 34.30% | -81.30 | MRK | /operating-margins <GO> |
| Net Profit Margin | -44.40% | 28.10% | -72.50 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -1.60% | 1.30% | -2.90 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 0.20 | 5.19 | -4.99 | MRK | /balance-sheet <GO> |
| Piotroski F-Score Quality | 6/9 | 7/9 | -1.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 75.5 | 51.7 | +23.80 | MYGN | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $638.0M | $361.02B | -$360.38B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | MYGN REV | MRK REV | MYGN GROSS % | MRK GROSS % | MYGN FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $824.5M | $65.01B | 69.9% | 74.8% | $1.8M | $12.36B |
| FY 2024 | $837.6M | $64.17B | 69.9% | 76.3% | -$8.7M | $18.10B |
| FY 2023 | $753.2M | $60.12B | — | — | -$110.9M | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
MYGN // BETA —
MRK // BETA 0.92